Evaluation Of Anti-PD-1 Cemiplimab Plus Anti-LAG-3 REGN3767 In Early-Stage, High-Risk HER2-Negative Breast Cancer: Results From The Neoadjuvant I-SPY 2 Trial
Cemiplimab;REGN-3767
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Evaluation Of Anti-PD-1 Cemiplimab Plus Anti-LAG-3 REGN3767 In Early-Stage, High-Risk HER2-Negative Breast Cancer: Results From The Neoadjuvant I-SPY 2 Trial ### Output: Cemiplimab;REGN-3767